Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24327726 | 0.78 | MAPT (0.41) | MAPTALDH1A1MEN1POLBKMT2A | |
| SCHEMBL28756655 | 0.74 | MAPT (0.50) | MAPTALDH1A1MEN1POLBKMT2A | |
| SCHEMBL14935736 | 0.73 | MAPT (0.40) | MAPTALDH1A1MEN1POLBKMT2A | |
| SCHEMBL6609230 | 0.72 | MAPT (0.49) | MAPTALDH1A1MEN1POLBKMT2A | |
| SCHEMBL15272291 | 0.71 | MAPT (0.47) | MAPTALDH1A1MEN1POLBKMT2A | |
| SCHEMBL12390037 | 0.71 | MAPT (0.43) | MAPTALDH1A1MEN1POLBKMT2A | |
| SCHEMBL17140165 | 0.71 | MAPT (0.43) | MAPTALDH1A1MEN1POLBKMT2A | |
| SCHEMBL5149643 | 0.71 | MAPT (0.40) | MAPTALDH1A1MEN1KMT2ACES2 | |
| SCHEMBL8355767 | 0.69 | MAPT (0.38) | MAPTALDH1A1MEN1POLBKMT2A | |
| Methoxymethane SCHEMBL28252357 | 0.69 | MAPT (0.50) | MAPTALDH1A1MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170182062-A1 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| US-9433631-B2 | 4-pregenen-11β-17-21-triol-3,20-dione derivatives | ALLERGAN, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150057258-A1 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN, INC. | 2015-02-26 | — | — | US | disclosed |
| US-8906892-B2 | 4-pregenen-11β-17-21-triol-3,20-dione derivatives | ALLERGAN, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130123223-A1 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123223-A1 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | NR3C2, HSD3B1, HSD3B2 | MAPT 2235/4885ALDH1A1 2459/4885MEN1 1763/4885 |
| US-20170182062-A1 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | NR3C2, HSD3B1, HSD3B2 | MAPT 2235/4885ALDH1A1 2459/4885MEN1 1763/4885 |
| US-20150057258-A1 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | NR3C2, HSD3B1, HSD3B2 | MAPT 2235/4885ALDH1A1 2459/4885MEN1 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.